• PDF / 168,967 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 34 Downloads / 147 Views

DOWNLOAD

REPORT

---

1 S

Xerostomia: case report In a retrospective study of 16 patients with end stage metastatic castration resistant prostate cancer (mCRPC) receiving radioligand therapy with 225-actinium-PSMA between 08/18 and 12/19, a patient [age and sex not stated] was described, who developed severe grade 3 xerostomia during radioligand therapy with 225-actinium-PSMA [Ac-225 PSMA I&T] for mCRPC [dosage, route, time to reaction onset and outcome not stated]. Zacherl M, et al. First clinical results for radioligand therapy using the alpha emitter 255Ac- 225-PSMA II&T in patients with end stage mCRPC. Journal of Nuclear Medicine 61 (Suppl. 1): (plus oral presentation) abstr. 592, 1 May 2020. Available from: URL: http://jnm.snmjournals.org/content/61/ 803514887 supplement_1/592.abstract?sid=34a057bf-547a-4f75-982f-b52920c2cfce [abstract]

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Nov 2020 No. 1830